124 related articles for article (PubMed ID: 21431505)
1. Azacytidine for the treatment of myelodysplastic syndromes in the elderly.
Diez Campelo M; Delgado RG; Molias AC; Sanchez JF
Adv Ther; 2011 Mar; 28 Suppl 2():10-5. PubMed ID: 21431505
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloblastic leukemia.
Molina CA; Rodríguez MJ; de Marcos NS; Font P
Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.
Font P
Adv Ther; 2011 Mar; 28 Suppl 3():1-9. PubMed ID: 21431628
[TBL] [Abstract][Full Text] [Related]
4. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
6. Treatment of myelodysplastic syndromes in elderly patients.
Sanchez JF
Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Wijermans PW; Krulder JW; Huijgens PC; Neve P
Leukemia; 1997 Mar; 11 Suppl 1():S19-23. PubMed ID: 9130687
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Miyazaki Y; Kiguchi T; Sato S; Usuki K; Ishiyama K; Ito Y; Suzuki T; Taguchi J; Chiba S; Dobashi N; Tomita A; Harada H; Handa H; Horiike S; Maeda T; Matsuda M; Ichikawa M; Hata T; Honda S; Iyama S; Suzushima H; Moriuchi Y; Kurokawa T; Yokota K; Ohtake S; Yamauchi T; Matsumura I; Kiyoi H; Naoe T;
Int J Hematol; 2022 Aug; 116(2):228-238. PubMed ID: 35508695
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
10. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
11. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Santini V; Fenaux P; Mufti GJ; Hellström-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
Eur J Haematol; 2010 Aug; 85(2):130-8. PubMed ID: 20394651
[TBL] [Abstract][Full Text] [Related]
14. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine for the treatment of myelodysplastic syndromes.
Krawczyk J; Keane N; Freeman CL; Swords R; O'Dwyer M; Giles FJ
Expert Opin Pharmacother; 2013 Jun; 14(9):1255-68. PubMed ID: 23621771
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
19. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
20. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
